Nebenwirkungen · Cabazitaxel Accord
Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-144897 · Präparat HOS-099284
Cardiac disorders and arrhythmias In the pooled analysis, cardiac events were reported in 5.5% of the patients of which 1.1% had grade ≥3 cardiac arrhythmias. The incidence of tachycardia on cabazitaxel was 1.0%, of which less than 0.1% were grade ≥3. The incidence of atrial fibrillation was 1.3%. Cardiac failure events were reported for 2 patients (0.2%), one of which resulted in a fatal outcome. Fatal ventricular fibrillation was reported in 1 patient (0.3%), and cardiac arrest in 3 patients (0.5%). None were considered related by the investigator.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-07T12:43:00Z · SHA-256 e94990ee8411fa544039e204cf256f3e804b1eb52641ffca9b2a77499ea7c894 · Passage fecddd8724bd4ffc95441df64a33f4154159d47c9986e0f1df861447df46f855 · Zeichen 14585–15141 im Abschnitt